Herantis Pharma's clinical study with Lymfactin advances to high dose level
Herantis Pharma's clinical study with Lymfactin advances to high dose level Herantis Pharma PlcCompany release 6 March 2017 at 10:00 am Herantis Pharma Plc's ("Herantis") clinical study with the company's innovative gene therapy investigational product Lymfactin® for the treatment of secondary lymphedema has advanced to highest planned dose level owing to good reported safety. A Data Monitoring Committee of independent experts recommended proceeding to high dose treatments after assessing safety data on the previously treated patients. Following the recommendation, the first high